GlassScriptPhysician profile
Aryan Mashid
NPI 1902274574
$4,013.33
in general payments reported to CMS, 2019-2025
19 companies · $854 in 2025
The $854 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $252 · 2021: $227 · 2022: $550 · 2023: $1,013 · 2024: $988 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659 · Long Term Medical Supply Or Device Loan: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.26 |
| Long Term Medical Supply Or Device Loan | $195.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,045.40 | 2019-2025 | Cequa |
| Abbvie INC. | $739.66 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $389.44 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $262.61 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $242.38 | 2021-2023 | |
| Carl Zeiss Meditec USA, INC. | $195.37 | 2023 | Cirrus 5000 With Angioplex |
| Kala Pharmaceuticals, INC. | $192.16 | 2020-2022 | |
| Allergan, INC. | $184.10 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $180.87 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Alcon Vision LLC | $139.59 | 2023-2025 | Tryptyr, Eysuvis, Argos |
| Dompe US, INC. | $87.01 | 2023-2025 | Oxervate |
| Rxsight INC | $74.25 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Amgen INC. | $61.86 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.19 | 2019-2021 | |
| Biotissue Holdings INC. | $55.07 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $30.01 | 2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $27.15 | 2022 | |
| Eyevance Pharmaceuticals LLC | $25.28 | 2020 | |
| Aerie Pharmaceuticals, INC. | $20.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aryan Mashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.